Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706355 | 0.76 | TSHR (0.52) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL27565434 | 0.75 | ALDH1A1 (0.46) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL507483 | 0.74 | TSHR (0.50) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL2281974 | 0.74 | TSHR (0.50) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL6988143 | 0.74 | TSHR (0.50) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL10415351 | 0.74 | TSHR (0.50) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL13440 | 0.74 | TSHR (0.50) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL506977 | 0.74 | TAAR1 (0.52) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL6491100 | 0.73 | CYP2C19 (0.57) | TSHRALDH1A1PTPN1DAOCA1 | |
| SCHEMBL4533282 | 0.72 | TSHR (0.48) | TSHRALDH1A1PTPN1KCNN4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9666904-B2 | Secondary battery | NEC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20150194703-A1 | SECONDARY BATTERY | NEC CORPORATION (JP) | 2015-07-09 | — | — | US | disclosed |
| US-20150037667-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND SECONDARY BATTERY USING SAME | NEC CORPORATION (JP) | 2015-02-05 | — | — | US | disclosed |
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1583532-B1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| EP-1578745-B1 | BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| US-7230108-B2 | Quinoline derivatives as glucokinase ligands | ASTRAZENECA AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-20060079553-A1 | Quinoline derivatives as glucokinase ligands | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | disclosed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1583532-A1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | Astrazeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004045614-A1 | QUINOLINE DERIVATIVES AS GLUCOKINASE LIGANDS | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | GCK, PDK2, GCKR | TSHR 1843/4885ALDH1A1 337/4885PTPN1 3866/4885 |
| US-20060079553-A1 | Quinoline derivatives as glucokinase ligands | GCK, GCKR, GALK1 | TSHR 1247/4885ALDH1A1 1065/4885PTPN1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.